Pancreatic Cancer Research

ResearcherSichuan UniversityNo recent work listed

Huimin Lü

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0001-1744-3612; OpenAlex author ID A5028900026. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
21
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: 4 papers · 2020: 1 paper · 2021: 2 papers · 2022: 3 papers · 2023: 1 paper

Papers 13

  1. Single-minded homolog 2 as a potential prognostic signature and assessment of its correlation with immune cell infiltration in pancreatic cancer. Last author DOI 10.5114/pjp.2023.134317↗
  2. Prognostic value of systemic immune-inflammation index in patients with pancreatic cancer: a meta-analysis. Last author DOI 10.1007/s10238-021-00785-x↗
  3. Down-regulation of USP22 reduces cell stemness and enhances the sensitivity of pancreatic cancer cells to cisplatin by inactivating the Wnt/β-catenin pathway. Last author DOI 10.1016/j.tice.2022.101787↗
  4. LncRNA GAS8-AS1 is a Novel Prognostic and Diagnostic Biomarker for Pancreatic Cancer. Co-author DOI 10.1615/critreveukaryotgeneexpr.2022039770↗
  5. Clinical characteristics and treatment analysis of pancreatic acinar cell carcinoma: A single institutional comparison to pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.suronc.2021.101528↗
  6. Long Non-Coding RNA MIR4435-2HG Promotes Glycolysis and Tumor Immunity in Pancreatic Cancer Through Absorption of microRNA-582-5p to Target GPX8 Co-author DOI 10.21203/rs.3.rs-1112369/v1↗
  7. miR-25 expression is upregulated in pancreatic ductal adenocarcinoma and promotes cell proliferation by targeting ABI2. Co-author DOI 10.3892/etm.2020.8595↗
  8. The oncological safety in minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Co-author DOI 10.1038/s41598-018-37617-0↗
  9. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy. Co-author DOI 10.1042/bsr20181374↗
  10. Downregulation of LINC01638 lncRNA inhibits migration and invasion of pancreatic ductal adenocarcinoma cells by reducing TGF‑β signaling. Co-author DOI 10.3892/mmr.2019.10699↗
  11. Linc-pint inhibits early stage pancreatic ductal adenocarcinoma growth through TGF-β pathway activation. Co-author DOI 10.3892/ol.2019.10111↗
  12. Deregulated expression of miR-107 inhibits metastasis of PDAC through inhibition PI3K/Akt signaling via caveolin-1 and PTEN. Co-author DOI 10.1016/j.yexcr.2017.10.033↗
  13. CA19-9 as a predictor of resectability in patients with borderline resectable pancreatic cancer. First author DOI 10.5754/hge12921↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Li Mao · 8 shared papers, 2019–2023 · strength 1.12
  2. DuJiang Yang · 8 shared papers, 2019–2023 · strength 1.06
  3. Weiming Hu · 8 shared papers, 2017–2022 · strength 1.03
  4. Zhenlu Li · 3 shared papers, 2021–2022 · strength 0.55
  5. Junjie Xiong · 3 shared papers, 2017–2021 · strength 0.33
  6. Xing Huang · 1 shared paper, 2022 · strength 0.22
  7. Zuowei Wu · 1 shared paper, 2023 · strength 0.19
  8. Qian Hu · 1 shared paper, 2023 · strength 0.19
  9. Zihe Wang · 1 shared paper, 2022 · strength 0.19
  10. Ling Zhang · 1 shared paper, 2022 · strength 0.17
  11. Xing Huang · 1 shared paper, 2021 · strength 0.16
  12. Bole Tian · 1 shared paper, 2021 · strength 0.16
  13. Weiming Hu · 1 shared paper, 2021 · strength 0.14
  14. Ling Zhang · 1 shared paper, 2019 · strength 0.11
  15. Xu-Bao Liu · 1 shared paper, 2017 · strength 0.06
  16. Ailin Wei · 1 shared paper, 2017 · strength 0.06
  17. Ang Li · 1 shared paper, 2017 · strength 0.06
  18. Chunlu Tan · 1 shared paper, 2017 · strength 0.06
  19. Dan Wang · 1 shared paper, 2017 · strength 0.06
  20. Bole Tian Zhaoda · 1 shared paper, 2013 · strength 0.05
  21. Zhao-Peng He · 1 shared paper, 2013 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.